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Abstract
Background: Antibiotics are a major tool in the WHO’s trachoma control program. Even a single mass distribution reduces
the prevalence of the ocular chlamydia that causes trachoma. Unfortunately, infection returns after a single treatment, at
least in severely affected areas. Here, we test whether additional scheduled treatments further reduce infection, and
whether infection returns after distributions are discontinued.
Methods: Sixteen communities in Ethiopia were randomly selected. Ocular chlamydial infection in 1- to 5-year-old children
was monitored over four biannual azithromycin distributions and for 24 months after the last treatment.
Findings: The average prevalence of infection in 1- to 5-year-old children was reduced from 63.5% pre-treatment to 11.5%
six months after the first distribution (P,0.0001). It further decreased to 2.6% six months after the fourth and final treatment
(P= 0.0004). In the next 18 months, infection returned to 25.2%, a significant increase from six months after the last
treatment (P= 0.008), but still far lower than baseline (P,0.0001). Although the prevalence of infection in any particular
village fluctuated, the mean prevalence of the 16 villages steadily decreased with each treatment and steadily returned after
treatments were discontinued.
Conclusion: In some of the most severely affected communities ever studied, we demonstrate that repeated mass oral
azithromycin distributions progressively reduce ocular chlamydial infection in a community, as long as these distributions
are given frequently enough and at a high enough coverage. However, infection returns into the communities after the last
treatment. Sustainable changes or complete local elimination of infection will be necessary.
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Introduction
Trachoma remains a leading cause of blindness in poor, arid
areas such as sub-Saharan Africa[1]. The World Health
Organization (WHO) has targeted the disease in a control
program, relying in part on repeated mass distributions of oral
azithromycin to reduce the prevalence of the ocular chlamydial
infection that causes the disease[2]. The program has had
remarkable success in areas with moderate levels of infection
and in areas where socioeconomic improvements are occurring in
concert with the trachoma program. Even a single distribution can
dramatically reduce the prevalence of chlamydia[3,4,5,6]. In
modestly infected communities, infection may then remain low[5].
In fact, in some areas, infectious trachoma is decreasing even in
the absence of treatment[7,8,9]. However in severely affected
communities, infection clearly returns after a single mass
distribution, and repeated treatments will be necessary[10,11,12].
It is unknown whether scheduled, repeated distributions will
progressively reduce infection, and for how long distributions will
need to be given[10,13]. In a previous study in southern Ethiopia,
infection returned in the first 6 months after treatment at a rate
that suggested that biannual treatment would be necessary for
progressive reduction with each distribution[10,14]. Here we
present longer term results from these same villages, assessing the
effect of four biannual distributions, and determining whether or
not infection returns after treatments have been discontinued.
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Methods
From the district record of the Enemore district of the Gurage
Zone, southern Ethiopia, a simple random sample was chosen of
16 kebele (a government unit which in this area includes
approximately 5 villages). A single random village was selected
from each of 16 randomly chosen kebele as previously
described[10]. Selected villages were given four biannual,
community-wide antibiotic distributions starting in March 2003.
At scheduled treatments, those aged 1 year and older were offered
a single dose of directly observed, oral azithromycin (1 g in adults
or 20 mg/kg in children). Pregnant women and those allergic to
macrolides were offered a 6-week course of topical 1% tetracycline
ointment (applied twice daily to both eyes and not directly
observed).
All children aged 1–5 years in treated villages were examined
and assessed for the presence of ocular chlamydial infection
(defined by a positive PCR test), at baseline (pre-treatment), and 6,
12, 18, 24, 30, 36, and 42-months post-treatment. Examination
was performed using the WHO’s simplified grading system, with
clinical activity being defined as a grade of TF (5 more follicles on
the upper tarsal conjunctiva) or TI (intense inflammation of the
conjunctiva obscuring more than half of the normal, underlying
conjunctival vasculature)[15]. A dacron swab was passed firmly
across the right upper tarsal conjunctiva three times, rotating
between each pass. In a randomly selected sample of 5 children
per village, a duplicate field control was taken in an identical
manner to the initial swab. In a separate 5 randomly chosen
children per village, a negative field control was obtained
immediately after the initial swab by passing a swab within one
inch of the subject’s conjunctiva. Examiners then changed gloves
for the next subject (whether or not the child had been selected as
a control). All samples were kept at 4uC in the field and frozen at
220uC within 6 hours. The swabs were shipped at 4uC to San
Francisco where they were stored at 270uC until processed. The
Amplicor PCR test (Roche Diagnostics, Branchburg, NJ) was used
to detect chlamydial DNA. Pre-treatment samples were tested
individually. Post-treatment samples from the same village were
randomized and pooled into groups of 5, with a possible
remainder pool of 1–4 samples. Each pool was then tested
according to the Amplicor protocol[16,17]. If PCR of any pool
was equivocal, then all samples from the pool were individually re-
tested. The prevalence of ocular chlamydial infection in each
village was obtained by maximum likelihood estimation[10,12,14].
The number of positive individual samples most likely to have
resulted in the observed pooled PCR results was chosen as the
estimate for that village (Mathematica 5.0, Wolfram Research Inc.,
Champaign, IL). If 2/3 or more of the pools were positive, the
individual samples were re-pooled randomly into groups of two
and re-processed to allow more accurate estimation[17]. Lab
personnel were masked to the identification of the village and the
individual. The mean village prevalence of infection at different
visits was compared using the paired T-test in STATA 9.0.
At the time of each procedure, informed consent was obtained
verbally from all participants by trained Ethiopian staff in the
local language, Amharic. Written consent was not deemed
appropriate, given the low literacy rate in the region.
Participants and guardians were assured that they would receive
the same care, regardless of their participation in the monitoring
program. Ethical approval for this study was obtained from the
Committee for Human Research of the University of California,
San Francisco and the Ethiopian Science and Technology
Commission; the study was carried out in accordance with the
Declaration of Helsinki. The study is registered at www.
clinicaltrials.gov as trial number NCT00221364. The CON-
SORT protocol and checklist are noted as Figure 1 and
Checklist S1, respectively.
Results
In the baseline census, the 16 villages contained 5735
individuals in 1348 households. There were 808 1–5 year-old
children, 48.6% of whom were girls (95% CI 45.3 to 51.9%). In
these children, the mean prevalence of clinical activity (defined as
either TF or TI in the WHO simplified grading scale), was 91.6%
(95% CI 87.8 to 95.5%). The mean coverage of antibiotic at a
village visit was 94.1% relative to the census, ranging from 73.9%
to 100% of those eligible for treatment (Table 1). The first
treatment reduced infection in all 16 villages, and the next three
treatments further reduced the prevalence in 14 of 16 villages.
Infection increased in the 24 months after the last treatment in 14
of 16 villages, but remained lower than it had been before the first
treatment in all 16 villages. The mean prevalence was reduced
from 63.5% at baseline (range 26.3% to 85.7%) to 11.5% six
months after the first treatment range (0.0 to 24.4%) as previously
described (P,0.0001)[10]. The next three biannual distributions
continued to reduce the prevalence to 2.6% (range 0.0% to 7.0%),
a significant decrease from after a single treatment (P=0.0004).
From 6 to 24 months after the last treatment (the 24 and
42 month visits), infection had returned to an average of 25.2%
(range 2.0% to 70.0%). At 24 months after the last treatment, the
mean prevalence of infection was far higher than at 6 months after
the last treatment (P=0.008), but was still only 40% of that at
baseline (P,0.0001).
The 16 villages varied widely in their pre-treatment and post-
treatment prevalence, and in how rapidly infection returned after
treatments had been discontinued (Figure 2). There was a
statistically significant correlation between the prevalence of
infection at baseline and at 6 months (r = 0.51, P=0.05), but a
lower correlation between baseline and 42 months (r = 0.36,
P=0.17). 625 of 630 duplicate field controls were concordant
(99.2%, 95% CI 98.2 to 99.7%). 625 of 632 negative field controls
from baseline to the 42 month visit showed no evidence of
chlamydia. (98.9%, 95% CI 97.7 to 99.6%).
Author Summary
Trachoma is one of the leading causes of blindness in the
developing world. The World Health Organization has a
multi-pronged approach to controlling the ocular chla-
mydial infection that causes the disease, including
distributing antibiotics to entire communities. Even a
single community treatment dramatically reduces the
prevalence of the infection. Unfortunately, infection
returns back into communities after treatment, at least in
severely affected areas such as rural Ethiopia. Here, we
assess whether additional scheduled treatments in 16
communities in the Gurage area of Ethiopia further reduce
infection, and whether the disease returns after distribu-
tions are stopped. In communities with the highest levels
of trachoma ever studied, we find that repeated mass oral
azithromycin distributions gradually reduce the prevalence
of trachoma infection in a community, as long as these
treatments are given frequently enough and to enough
people in the community. Unfortunately, infection returns
into the communities after the last treatment. Sustainable
changes or complete local elimination of infection will be
necessary to stop the return of ocular chlamydial in
communities with very high prevalence of the disease.
Infectious Trachoma in Ethiopia
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Figure 1. CONSORT Flowchart.
doi:10.1371/journal.pntd.0000376.g001
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Discussion
It has been well documented that a single mass distribution of
oral azithromycin to a trachoma-endemic community can lower
the prevalence of ocular chlamydial infection. This has been
demonstrated in group-randomized trials in Egypt, Tanzania, the
Gambia, and a nearby area of Ethiopia and in observational
studies in Tanzania, the Gambia, Nepal, and Viet-
nam[3,4,5,6,11,12,18]. This is true in even the most severely
affected communities such as those followed in this study[10].
Table 1. Estimated Antibiotic Coverage at Each Village Visit.
Village Total population Antibiotic Coverage
Baseline (%) 6-Months (%) 12-Months (%) 18-Months (%)
1 523 95.8% 95.7% 98.1% 98.4%
2 572 84.8% 95.8% 98.0% 97.1%
3 365 94.5% 96.4% 94.2% 96.5%
4 708 95.6% 96.9% 96.6% 98.6%
5 621 96.7% 96.6% 93.8% 95.0%
6 670 95.8% 93.5% 97.4% 97.3%
7 386 85.9% 83.3% 83.0% 91.5%
8 306 97.4% 94.4% 96.2% 93.3%
9 241 99.6% 99.5% 100.0% 97.3%
10 122 97.2% 88.6% 96.8% 88.6%
11 213 85.6% 96.4% 88.5% 87.7%
12 184 73.9% 98.8% 90.8% 94.3%
13 183 93.0% 95.3% 99.3% 91.0%
14 599 85.1% 90.0% 98.0% 96.2%
15 290 93.4% 95.3% 100.0% 92.3%
16 898 96.4% 96.4% 97.1% 95.8%
Mean 430 91.9% 94.6% 95.5% 94.4%
94.1% relative to the census, ranging from 73.9% to 100%.
doi:10.1371/journal.pntd.0000376.t001
Figure 2. The Mean Prevalence of Infection. The mean prevalence of infection (black) and the prevalence in each of the individual 16 study
villages (grey) are plotted against time. Points represent estimates of the prevalence of infection in 1–5 year-old children at a single village-visit. Lines
connecting points were constructed for illustrative purposes in three ways. Before the first treatment, infection was presumed to be constant. After
each treatment (black arrow), infection was presumed to decrease by the estimated coverage level, before returning in the subsequent 6 months to
the observed prevalence. After the last treatment, infection was presumed to proceed linearly between each time point.
doi:10.1371/journal.pntd.0000376.g002
Infectious Trachoma in Ethiopia
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However, if infection is not locally eliminated, it returns back into
a community after a single mass distribution, at least in severely
affected areas, so repeated distributions will be neces-
sary[10,11,12].
In a single, moderately affected community in Nepal, infection
was reduced from 26% in children pre-treatment to a single
infection (0.5%) after 3 annual treatments[4]. However, it has not
been clear whether repeated, scheduled treatments can progres-
sively reduce the prevalence of infection in the most severely
affected areas. This is theoretically possible even in hyper-endemic
settings, as long as distributions reduce infection more than it
returns between treatments. Simple mathematical modes suggest
that a progressive reduction is dependant on the coverage and
frequency of distributions, and the rate that infection returns into a
particular community[10,13]. We have previously estimated that
success in an area with disease as severe as seen in this part of
Ethiopia could be achieved with biannual distributions [10,13,19].
In the 16 villages studied in this report, each subsequent treatment
further lowered the mean prevalence. Infection after four
treatments was significantly lower than after one treatment. Thus
the prevalence of infection can be progressively reduced with each
repeated distribution, at least when treatments are given
biannually and at a relatively high level of coverage.
Perhaps the major unanswered question concerning mass
antibiotic distributions for trachoma is whether mass antibiotic
distributions can be discontinued, and if so, when[20]. If infection
is not locally eliminated, will it simply return into communities
after the last treatment? Some have hypothesized that infection
may never return if it is brought to a low enough level, analogous
to the Allee effect found in population biology[13,21,22,23,24].
Infection has been shown to return after a single treatment in some
communities, but not in others[12,25]. The results of this study
indicate that even after four biannual treatments, if distributions
are discontinued, infection predictably returns. The prevalence
was lowered to an average of 2.6% prevalence after the four
biannual treatments, but in the two years after the last treatment,
infection had returned 10-fold to 25.2%.
There is a great deal of variation between villages, even in the
same geographical area. It is tempting to speculate that
underlying differences between the villages explain this variance.
However, it should be noted that there is also considerable
variation in the prevalence of the same village over time. Village
2 had the lowest prevalence at 12 months and one of the highest
at 42 months (Table 2). Village 11 had the highest prevalence at
18 months and the lowest at 42 months. Village 9 had one of the
highest prevalences pre-treatment and one of the lowest at
42 months. None of these anomalies can be explained by the
treatment coverage. However, the variability of these results is
well within that suggested by stochastic mathematical models,
which account for the effect of chance[19,26]. As expected in
longitudinal data with unexplained variance, the correlation
between each time point decreases over larger time periods. The
correlation coefficient between baseline prevalence and
24 month prevalence is well below 0.5. This has important
ramification for the design of trachoma studies, since it suggests
that using the change of prevalence from baseline actually results
in more variance (and less information) then using the post-
treatment result alone[27].
It is not clear from where infection returns. At 21 of the 128
total village visits (16 villages68 vists), no infection could be
identified in 1–5 year-old children. At 10 of the 21 subsequent
visits in the same villages, infection returned to 1–5 year-old
children. Re-infection of this 1–5 year-old age group could have
come from many sources. Infected individuals outside the 1–5
year-old age group would have gone undetected and could have
infected 1–5 year-old children before the next treatment. Even if
infection were truly locally eliminated from a community, it may
be re-introduced from the outside. All communities in the district
Table 2. Estimated Prevalence of Infection at Each Village Visit.
Estimated Prevalence of Infection in 1–5 Year-Old Children %(infected/total)
village baseline 6 month 12 month 18 month 24 month 30 month 36 month 42 month
1 60.5%(23/38) 23.1%(9/39) 5.3%(2/38) 2.8%(1/36) 4.3%(2/47) 12.8%(5/39) 10.7%(6/56) 28.6%(12/42)
2 85.7%(60/70) 11.6%(8/69) 0.0%(0/65) 0.0%(0/62) 2.9%(1/35) 6.7%(2/30) 10.0%(3/30) 64.5%(20/31)
3 26.3%(10/38) 2.2%(1/45) 12.0%(6/50) 7.0%(3/43) 1.5%(1/65) 4.5%(3/67) 19.4%(13/67) 20.0%(13/65)
4 69.9%(65/93) 10.1%(9/89) 10.7%(11/103) 3.5%(3/86) 0.0%(0/107) 3.0%(3/100) 5.1%(6/117) 28.1%(32/114)
5 72.6%(45/62) 7.6%(5/66) 10.8%(7/65) 4.8%(3/63) 1.6%(1/61) 4.4%(2/45) 1.9%(1/52) 7.0%(4/57)
6 63.7%(58/91) 24.4%(19/78) 8.2%(9/110) 2.4%(2/84) 1.0%(1/105) 0.0%(0/118) 3.3%(4/121) 21.0%(26/124)
7 65.0%(39/60) 20.0%(13/65) 7.8%(4/51) 9.8%(4/41) 2.7%(2/73) 9.7%(6/62) 28.8%(21/73) 52.9%(37/70)
8 72.2%(26/36) 13.9%(5/36) 0.0%(0/26) 0.0%(0/34) 7.0%(3/43) 5.9%(2/34) 13.9%(5/36) 14.3%(5/35)
9 81.0%(17/21) 10.0%(2/20) 20.0%(6/30) 8.0%(2/25) 5.9%(2/34) 2.9%(1/34) 4.8%(2/42) 5.0%(2/40)
10 42.9%(6/14) 0.0%(0/13) 0.0%(0/11) 0.0%(0/18) 6.3%(1/16) 6.7%(1/15) 5.0%(1/20) 34.8%(8/23)
11 63.0%(17/27) 11.5%(3/26) 42.3%(11/26) 8.7%(2/23) 3.2%(1/31) 2.9%(1/34) 5.1%(2/39) 2.0%(1/51)
12 79.2%(19/24) 15.2%(5/33) 33.3%(8/24) 6.3%(2/32) 3.0%(1/33) 7.0%(3/43) 68.3%(28/41) 70.0%(28/40)
13 50.0%(8/16) 0.0%(0/13) 0.0%(0/16) 0.0%(0/16) 0.0%(0/19) 15.0%(6/40) 9.7%(3/31) 3.0%(1/33)
14 81.4%(57/70) 19.4%(13/67) 3.5%(2/57) 1.8%(1/56) 0.0%(0/69) 6.3%(6/95) 14.9%(13/87) 36.3%(29/80)
15 44.8%(13/29) 10.0%(3/30) 0.0%(0/32) 0.0%(0/43) 0.0%(0/38) 0.0%(0/55) 0.0%(0/60) 8.6%(5/58)
16 58.0%(69/119) 5.6%(7/126) 0.0%(0/93) 0.9%(1/108) 1.7%(2/115) 0.0%(0/113) 0.8%(1/123) 6.4%(6/94)
mean
(95%CI)
63.5%
(54.9%–72.2%)
11.5%
(7.5%–15.6%)
9.6%
(2.9%–16.3%)
3.5%
(1.6%–5.3%)
2.6%
(1.3%–3.8%)
5.5%
(3.2%–7.8%)
12.6%
(3.7%–21.5%)
25.2%
(13.5%–36.7%)
doi:10.1371/journal.pntd.0000376.t002
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received the first two biannual distributions as part of the ORBIS
trachoma program, but re-infection from neighboring areas
needs to be considered. Examination of individual village results
suggests that re-introduction may not occur for a period of time.
We were unable to identify any infection in Village 15 for 2K
years after the second treatment. Note also that in many of the
communities in this study, reinfection from neighboring villages
need not even be posited, as infection clearly remained in the
village itself.
The WHO-recommended mass azithromycin distributions are
remarkably successful in reducing the prevalence of infectious
trachoma, even in the most severely affected areas. In these 16
communities, the average prevalence of infection in 1–5 year-old
children was reduced 7-fold six months after a single mass
antibiotic distribution. Three subsequent biannual treatments
reduced the prevalence to a total of 25-fold from baseline.
Unfortunately, infection clearly returned in the 24 months after
treatments were discontinued, although it had still only reached
40% of baseline prevalence. There are several ways that trachoma
programs could become sustainable. Interventions such as hygiene
education or latrine construction could be shown to prevent
infection from returning. Although this has yet to be demonstrat-
ed, there are reasons to be optimistic, and these interventions are
considered an important part of the WHO’s overall trachoma
strategy[28,29,30,31]. Antibiotic distributions could be continued
indefinitely, although this raises issues of cost, resistance, and loss
of immunity[18,32,33,34,35,36,37]. A secular trend outside of the
trachoma program may assist in the elimination of trachoma, as
has been described in several other settings[7,8,9,12,25]. Finally, if
infection can be eliminated locally, then this offers a higher level of
sustainability[12,19,22].
Supporting Information
Checklist S1 CONSORT Checklist. Statement of requirements
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